Heron Announces Positive Topline Results from Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast Augmentation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Two More Positive HTX-011 Studies Supports Bullish Heron Therapeutics (HRTX) Thesis - Cantor Fitzgerald
June 21, 2018 10:47 AM EDTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $40 price target on Heron Therapeutics (NASDAQ: HRTX) announced positive top-line results from two additional studies which will support the NDA filing for HTX-011 and expand the commercial opportunity for the drug.
"This... More
Heron Therapeutics (HRTX) Says HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDA
June 21, 2018 8:05 AM EDTHeron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that HTX-011 for postoperative pain management has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA). HTX-011 is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the management of postoperative pain.
Breakthrough Therapy designation is designed to expedite the development... More
